Telix doses first patient in Phase 3 renal cancer trial
July 21, 2026 | 14:41
Telix Pharmaceuticals dosed the first patient in its Phase 3 LUTEON trial evaluating TLX250-Tx for relapsed or recurrent clear cell renal cell carcinoma, marking the first Phase 3 study of a CAIX-targeted radiopharmaceutical in this cancer type.
Mobile Version